Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.

Jia L, Ma Y, Rong S, Betters JL, Xie P, Chung S, Wang N, Tang W, Yu L.

J Lipid Res. 2010 Nov;51(11):3135-44. doi: 10.1194/jlr.M006353. Epub 2010 Aug 10.

2.

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T.

J Gastroenterol. 2011 Jan;46(1):101-7. doi: 10.1007/s00535-010-0291-8. Epub 2010 Jul 24.

PMID:
20658156
3.

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study.

Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A.

Hepatol Res. 2010 Jun;40(6):566-73. doi: 10.1111/j.1872-034X.2010.00644.x. Epub 2010 Apr 14.

PMID:
20412324
4.

Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.

Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH.

Diabetes Care. 2010 May;33(5):1134-9. doi: 10.2337/dc09-1765. Epub 2010 Feb 25.

5.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

Vuppalanchi R, Chalasani N.

Hepatology. 2009 Jan;49(1):306-17. doi: 10.1002/hep.22603. Review.

6.

Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes.

Fahmi S, Yang C, Esmail S, Hobbs HH, Cohen JC.

Hum Mol Genet. 2008 Jul 15;17(14):2101-7. doi: 10.1093/hmg/ddn108. Epub 2008 Apr 15.

7.

Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels.

Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, Hobbs HH.

Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1810-5. Epub 2006 Jan 31.

8.

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7. Epub 2005 May 31.

9.

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH.

Hepatology. 2004 Dec;40(6):1387-95.

PMID:
15565570
10.

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL.

Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8. Epub 2004 Aug 31.

Supplemental Content

Support Center